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M A J O R A R T I C L E
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Independently in a Single Population
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Omar Triana-Chávez,2 and John M. Kelly1
1Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, and 3School of Biological and Chemical Sciences,
Queen Mary, University of London, United Kingdom; 2Instituto de Biología, Universidad de Antioquia, Medellín, Colombia
Benznidazole is the frontline drug used against Trypanosoma cruzi, the causative agent of Chagas disease.
However, treatment failures are often reported. Here, we demonstrate that independently acquired mutations
in the gene encoding a mitochondrial nitroreductase (TcNTR) can give rise to distinct drug-resistant clones
within a single population. Following selection of benznidazole-resistant parasites, all clones examined had
lost one of the chromosomes containing the TcNTR gene. Sequence analysis of the remaining TcNTR allele
revealed 3 distinct mutant genes in different resistant clones. Expression studies showed that these mutant
proteins were unable to activate benznidazole. This correlated with loss of ﬂavin mononucleotide binding.
The drug-resistant phenotype could be reversed by transfection with wild-type TcNTR. These results identify
TcNTR as a central player in acquired resistance to benznidazole. They also demonstrate that T. cruzi has a
propensity to undergo genetic changes that can lead to drug resistance, a ﬁnding that has implications for
future therapeutic strategies.
Chagas disease is caused by Trypanosoma cruzi, a ﬂa-
gellated protozoan parasite transmitted by blood-
sucking triatomine bugs. In Latin America, 10 million
people are infected, with >15 000 deaths annually [1].
Because of migration, the disease is also undergoing
globalization. In the United States, there are an esti-
mated 300 000 infected individuals [2]. Chagas disease
has 3 phases; acute, indeterminate and chronic. The
acute stage is usually asymptomatic, although it can
present as a febrile-like illness in children and young
adults, with a fatality rate up to 5%. Most symptoms
resolve within 4–6 weeks, and patients then enter the
indeterminate stage. In the majority of cases, active
disease does not proceed further. However, approxi-
mately 30% of individuals progress to the chronic
phase, a process that can occur many years after the
initial infection. This can result in serious cardiac and
digestive tract pathologies, where prognosis is poor.
There is no immediate prospect of a Chagas disease
vaccine, and infection is lifelong. Chemotherapy is
therefore of major importance. For many years, benzni-
dazole and nifurtimox have been the only drugs avail-
able [3]. However, their use is characterized by toxicity,
and their efﬁcacy against chronic stage disease is unreli-
able. In addition, cases refractory to treatment are com-
monly reported [4], and drug-resistant parasites can be
selected in the laboratory [5, 6]. Benznidazole and nifur-
timox are nitroheterocyclic compounds that contain a
nitro group linked, respectively, to an imidazole and
furan ring [3]. They are prodrugs and require nitrore-
ductase (NTR)–catalyzed activation within the parasite
to have trypanocidal effects. Two classes of NTR have
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been identiﬁed in trypanosomes. Type II NTRs are O2-sensitive
ﬂavin-containing enzymes that are capable of 1-electron reduc-
tion of nitro drugs to generate an unstable nitro radical [7]. In
the presence of O2, this can lead to the production of superox-
ide anions and regeneration of the parent nitro compound, a
process known as redox cycling [8, 9]. Although activation of
nitroheterocyclic drugs by T. cruzi has been associated with the
formation of reactive oxygen species (ROS) and candidate re-
ductases have been implicated, there is no evidence that en-
hancing the parasite oxidative defense system has a protective
affect [10–15]. Furthermore, addition of benznidazole to
T. cruzi extracts does not lead to the generation of ROS [16].
Type I NTRs are O2-insensitive ﬂavin mononucleotide–
dependent enzymes that can mediate the 2-electron reduction
of nitro drugs through a nitroso, to hydroxylamine derivatives.
These can react further to generate nitrenium cations and
other highly electrophilic intermediates, which may promote
damage to DNA and other macromolecules [17, 18]. Two
enzymes with type I activity have been identiﬁed in T. cruzi.
The ﬁrst is prostaglandin F2α synthase [19], although this is
only capable of mediating 2-electron reduction under anaero-
bic conditions. The second, for which there is now strong
evidence of a central role in activating nitro drugs, is a nico-
tinamide adenine dinucleotide, reduced (NADH)–dependent
mitochondrial type I NTR [5]. In the case of nifurtimox, an
active unsaturated open chain nitrile metabolite contributes to
the resulting trypanocidal activity [20].
TcNTR can reduce a range of nitroheterocycles, and dele-
tion of the corresponding genes from T. cruzi and Trypanoso-
ma brucei results in loss of sensitivity [5]. Consistent with this,
a genome-wide RNA interference screen of T. brucei for genes
associated with nifurtimox and benznidazole resistance by
loss-of-function mechanisms identiﬁed TbNTR as the major
candidate [21]. To investigate the capacity of T. cruzi to
develop resistance against benznidazole, we generated resistant
clones following in vitro selection. Here, we show that distinct
drug-resistant clones can arise independently and that, in each
case, resistance under selective pressure is associated with loss
of TcNTR activity.
MATERIALS AND METHODS
Parasites
T. cruzi MRAT/COL/Gal61 (Table 1) [22] were cultivated in
supplemented Roswell Park Memorial Institute (RPMI) 1640
medium at 28°C [23]. Clones were derived by limiting dilu-
tion. Transformed T. cruzi were maintained at 10 μg/mL blas-
ticidin or 50 μg/mL G418. Amastigotes were grown in African
green monkey kidney (Vero) or rat skeletal myoblast L6 cells
cultured in RPMI 1640/10% fetal bovine serum at 37°C in 5%
CO2. To generate metacyclic trypomastigotes, epimastigote
cultures were grown to stationary phase, at which point they
differentiated. These were used to infect monolayers at a ratio
of 5 metacyclics per mammalian cell. Following overnight in-
cubation at 37°C, extracellular metacyclics and epimastigotes
were removed by several washes. Bloodstream-form trypomas-
tigotes emerged between day 7 and 10, and this homogenous
population was used in quantitative infection experiments.
Intact T. cruzi chromosomes were extracted using an
agarose-embedding technique [24] and were fractionated by
contour-clamped homogenous ﬁeld electrophoresis (CHEFE),
using a BioRad CHEFE Mapper. For analysis of natural benz-
nidazole sensitivity, TcNTR from 28 T. cruzi strains from dif-
ferent regions of Colombia was ampliﬁed and sequenced.
To generate benznidazole resistance, epimastigotes were
seeded at the median inhibitory concentration (IC50) and sub-
cultured for several weeks under selective pressure. The drug
concentration was then doubled and the process repeated.
This was continued until a resistant population was estab-
lished (61R) at 50 µM, the reported level of therapeutic resis-
tance [25]. IC50 values were determined by an enzymatic
micromethod [26]. A total of 2 × 106 epimastigotes/mL were
cultured with different drug concentrations for 72 hours at 28°
C in 96-well microtiter plates. The plates were then incubated
with 10 mg/mL 3(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetra-
zolium bromide (MTT) for 90 minutes and MTT reduction to
formazan crystals measured at 595 nm.
Construction of Vectors
For expression of TcNTR, a 708–base pair fragment corre-
sponding to the catalytic domain of the protein was ampliﬁed
using DNA from sensitive and resistant clones [5]. Fragments
were digested with BamHI/HindIII and ligated into the vector
pTrcHis-C (Invitrogen), and the resulting constructs were used
to transform Escherichia coli BL-21. To express active protein in
benznidazole-resistant T. cruzi, the full-length TcNTR gene
(939 bp) was ampliﬁed from 61S DNA and ligated into the
BamHI/HindIII site of the vector pTEX [27]. Parasites were
electroporated and transformants selected with G418. To gener-
ate TcNTR heterozygotes from 61S parasites, we used gene dis-
ruption with a construct containing a blasticidin-resistance
cassette [5]. All constructs were conﬁrmed by sequencing.
Biochemical Analysis
E. coli transformed with pTrcHis-TcNTR were treated with
isopropyl-β-D-thiogalactopyranoside to induce expression of
recombinant histidine-tagged proteins, which were puriﬁed on
nickel–nitriloacetic acid columns [5, 28]. Fractions were ana-
lyzed by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and protein concentrations determined by the BCA
assay (Pierce). TcNTR activity was measured by following the
changes in absorbance at 340 nm due to NADH oxidation.
The TcNTR ﬂavin cofactor was established by determining
the ﬂuorescence spectrum in acidic and neutral buffers [29].
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Puriﬁed protein (0.5 mg) was desalted and boiled for 5
minutes. Clariﬁed supernatant (90 µL) was then mixed with
10 µL 50 mM NaH2PO4 (pH = 7.6) or 1 M HCl (ﬁnal pH =
2.2), and the ﬂuorescence proﬁle was measured with a Gemini
Fluorescent Plate Reader (Molecular Devices). The mean ﬂuo-
rescence values (excitation λ = 450 nm; emission λ = 535 nm)
was determined and compared to ﬂavin mononucleotide and
ﬂavin adenine dinucleotide (FAD) standards.
RESULTS
Benznidazole-Resistant T. cruzi Lack One of the Chromosome
Bands Containing the TcNTR Gene
To select for benznidazole resistance, T. cruzi GAL61
(Table 1) were submitted to continuously increasing drug
pressure until we had established a population (61R) that grew
at a comparable rate in the presence or absence of 50 µM
benznidazole (Materials and Methods). This population dis-
played approximately 10-fold resistance. Six clonal lines
derived from this population exhibited 3–7-fold resistance,
when examined independently (Figure 1A). In the absence of
drug, the clones grew slightly slower in culture than the paren-
tal cells (doubling times from 28–42 hours, compared with 26
hours) but otherwise displayed no obvious morphological
changes. Previously, when we generated nifurtimox-resistant
T. cruzi, we found that they were also resistant to other nitro-
heterocyclic drugs, including benznidazole [5]. A similar
cross-resistance phenomenon was observed here, with 2-fold
greater resistance to nifurtimox and 4-fold greater resistance
to nitrofurazone (Figure 1B).
Table 1. Natural Sensitivity to Benznidazole Is Not Associated With TcNTR Sequence
Haplotype, Strain GenBank Accession No. Biological Origin Geographical Origin Phylogenetic Group IC50, μM
Haplotype 1
AC17 JN043349 Rhodnius pallescens Chocó I 6.53 ± 1.12
AMP07 JN043351 Panstrongylus geniculatus Antioquia I 17.6 ± 0.3
B114 JN043353 Triatoma dimidiata Córdoba I 18.7 ± 1.4
B138 JN043352 T. dimidiata Córdoba I 17.6 ± 0.7
B51 JN043354 R. pallescens Córdoba I 20.6 ± 1.1
CAS18 JN043345 Didelphis marsupialis Casanare I 3.90 ± 0.78
CG JN043336 Homo sapiens Caquetá II 4.61 ± 0.35
GAL52 JN043347 D. marsupialis Sucre I 9.07 ± 2.06
GAL61 JN043346 Rattus rattus Sucre I 5.85 ± 1.51
HA JN043337 H. sapiens Casanare I 4.66 ± 0.61
LB53 JN043358 T. dimidiata Sucre I 17.0 ± 0.7
MG JN043339 H. sapiens Arauca I 4.90 ± 0.33
MG10 JN043356 T. dimidiata Magdalena I 14.9 ± 0.89
OV1 JN043359 P. geniculatus Sucre I 17.4 ± 0.76
OV17 JN043355 P. geniculatus Sucre I 22.2 ± 2.4
SN3 JN043361 Rhodnius prolixus La Guajira I 34.6 ± 1.9
SN5 JN043360 R. prolixus La Guajira I 24.2 ± 1.3
SN6 JN043357 R. prolixus La Guajira I 16.9 ± 0.9
SP JN043342 H. sapiens Casanare I 6.41 ± 0.75
SPR JN043341 H. sapiens Casanare II 5.32 ± 1.08
STP33 JN043350 R. prolixus Tolima I 11.3 ± 1.0
Haplotype 2
AF1 JN043348 P. geniculatus Antioquia II 4.69 ± 1.87
JEM JN043340 H. sapiens Putumayo I 5.19 ± 0.65
Distinct haplotypes
DA JN043344 H. sapiens Boyacá I 32.8 ± 3.3
FCH JN043334 H. sapiens N.de Santander II 1.50 ± 0.51
MR JN043338 H. sapiens Cesar II 4.71 ± 0.29
W3534 JN043343 H. sapiens Sucre I 14.0 ± 1.3
YLY JN043335 H. sapiens Putumayo I/II 4.38 ± 0.24
TcNTR genes were amplified from DNA of 28 Colombian Trypanosoma cruzi strains and sequenced.
Abbreviation: IC50, median inhibitory concentration.
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Nifurtimox resistance in both T. cruzi and T. brucei has
been associated with downregulation or loss of a type I NTR
gene [5, 21]. We therefore examined the benznidazole-sensitive
and -resistant cells for changes in copy number at this locus.
In the sensitive parental cells (61S), TcNTR is a single copy
gene located on chromosome homologues of 1.1-Mb and
0.85-Mb. With the resistant parasites, however, the 0.85-Mb
band was missing in clonal and polyclonal populations
(Figure 1C, lanes 2 and 3). There were no other apparent
changes to the chromosome proﬁle. To determine whether
drug resistance was associated with loss of TcNTR rather than
another gene located elsewhere on the missing chromosome,
we reintroduced an active copy of TcNTR into 61R clone 2
[27] (Figure 1D). When the transformed cells were assessed,
we found that benznidazole sensitivity had been restored.
The Remaining TcNTR Allele in Each Benznidazole-Resistant
Clone Encodes an Inactive Protein
We next investigated whether the remaining chromosomal
copy of TcNTR in the benznidazole-resistant 61R parasites had
altered. Genes from the 6 resistant clones were ampliﬁed and
sequenced. Missense mutation(s) were identiﬁed in each case.
In clones 1, 2, 4, and 5, there was C/T transition at position
374, compared with the TcNTR gene ampliﬁed from sensitive
clones. In the protein, this would result in replacement of the
evolutionarily conserved Pro-125 with leucine (Figure 2). With
clone 6, in addition to the mutation at position 374, we also
identiﬁed a missense mutation at nucleotide 460 (C/G), giving
rise to the conversion of Pro-154 to alanine. For clone 3, there
was a single missense mutation resulting in C/G transversion
at nucleotide 477, leading to the replacement of Phe-159 with
leucine. No other mutations were observed in the TcNTR
genes isolated from the resistant clones. In the O2-insensitive
E. coli nitroreductase nfsB, most mutations associated with ni-
trofuran resistance are located in the corresponding region to
those in TcNTR (Figure 2) [30, 31].
To determine whether the TcNTR mutations had perturbed
activity, we ampliﬁed a fragment encoding the catalytic region of
the enzyme, using DNA from 61S and 61R clones 3, 4, and
6. TcNTR is mitochondrial, and previous attempts to express
active full-length enzyme had been unsuccessful [5]. Activity was
only detectable when the amino terminal domain was excluded
from the recombinant protein (Figure 2). After sequence conﬁr-
mation, the expressed histidine-tagged proteins were puriﬁed on
Figure 1. Properties of Trypanosoma cruzi clones derived by benznidazole selection. A Median inhibitory concentration (IC50) of benznidazole for
resistant parasites (61R noncloned population and clones 1–6) and parental (61S) cells (Materials and Methods). B, The 61R cells are cross-resistant to
the other nitroheterocycles nifurtimox and nitrofurazone. C, T. cruzi chromosomal DNA separated by contour-clamped homogenous ﬁeld electrophoresis
and hybridized with a TcNTR gene probe. Left panel, ethidium bromide–stained gel; right panel, autoradiograph of gel after Southern blotting. Lane 1,
parental 61S; lane 2, 61R clone 3; lane 3, 61R (noncloned population). D, Reintroduction of an active copy of TcNTR into benznidazole-resistant parasites
(61R clone 2), using the pTEX vector reverses the drug-resistance phenotype. Growth inhibition data are the mean (±SD) of 3 experiments. An autoradio-
graph (right) shows BamHI-digested DNA from parental 61R clone 2 (lanes 1 and 2) and pTEX-TcNTR–transformed cells (lanes 3 and 4) hybridized with
a TcNTR gene probe.
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nickel columns (Materials and Methods; Figure 3A). Fractions
containing recombinant protein derived from the 61S TcNTR
gene were yellow, as expected of a ﬂavoprotein. Those containing
enzyme derived from the resistant clones were colorless.
The capacity of the recombinant enzymes to reduce benzni-
dazole and nifurtimox was established from double reciprocal
plots of 1/TcNTR activity against 1/drug concentration, at a
ﬁxed NADH concentration (100 μM) (Materials and Methods;
Figure 3B and 3C). For the enzyme derived from the sensitive
clone, we established apparent Km values (±SD) of 28.0 ±
2.7 μM for benznidazole and 15.5 ± 3.5 μM for nifurtimox.
Further analysis gave apparent Vmax values (±SD) of 1824 ±
154 nmol NADH oxidized per minute per milligram for
benznidazole and 399 ± 14 nmol NADH oxidized per minute
per milligram for nifurtimox. When each of the mutant
TcNTRs were analyzed, no activity could be detected, even
when 10 times as much recombinant protein was used. We
then investigated the mutant proteins for ﬂavin binding
(Figure 3D), using ﬂuorescent detection under neutral and
acidic conditions (Materials and Methods). At neutral pH and
with an excitation wavelength of 450 nm, the ﬂavin mononu-
cleotide standard and 61S TcNTR-derived cofactor both gave a
ﬂuorescence proﬁle that peaked at 535 nm, a signal that was
quenched under acidic conditions. By contrast with FAD, the
535 nm peak occurs at pH2 and is quenched at pH7. No ﬂavin
ﬂuorescence was detected with mutant TcNTR protein
(Figure 3D).
Infectivity of Benznidazole-Resistant Parasites
To investigate the scope for drug resistance in the ﬁeld to
result from loss/inactivation of TcNTR genes, we examined the
effects of these events on infectivity. First, we generated het-
erozygous parasites to test for haploid insufﬁciency. One
TcNTR allele in the 61S genome was disrupted by targeted in-
tegration (Supplementary Figure 1). The 61S TcNTR+/− epi-
mastigotes grew at the same rate in culture as homozygotes,
and to the same density. When these heterozygotes were ex-
amined for benznidazole resistance, there had been a 4-fold
increase (Figure 4A). These parasites were used to infect rat
myoblast L6 cells. No differences were observed in the ability
of the heterozygotes to develop into infective metacyclic trypo-
mastigotes, to invade cells (Figure 4B), to grow as intracellular
amastigotes (Figure 4C), and subsequently to differentiate into
bloodstream trypomastigotes. Therefore, drug resistance that
arises through loss of 1 copy of TcNTR is not associated with
a reduction in infectivity in vitro.
The infective phenotype of the 61R resistant clones, which
contain a single inactive copy of TcNTR, was also examined. In
culture, epimastigotes differentiated into metacyclic trypomas-
tigotes at a level similar to sensitive clones. When culture-
derived trypomastigotes were used to initiate infections, all the
resistant clones tested (clones 3, 4, and 6) were able to develop
through the intracellular cycle as amastigotes and differentiate
into bloodstream trypomastigotes, which were released follow-
ing host cell lysis. At 2 levels, however, we observed a reduction
Figure 2. Mutations in TcNTR from benznidazole-resistant Trypanosoma cruzi. The TcNTR schematic identiﬁes the amino terminal extension (excluded
from recombinant proteins) and the location of putative ﬂavin mononucleotide (FMN)–binding regions inferred by analogy with Escherichia coli nfsB
[30]. Full-length copies of TcNTR from 61R resistant clones were ampliﬁed and sequenced. Differences in the amino acid sequence as compared to the
parental TcNTR (61S) were restricted to a single region and are highlighted in red. Several 61S clones were sequenced, but no differences were
identiﬁed. The sequence in this region of 61S TcNTR (residues 112–162) is identical to that in the genome strain CL Brener (GenBank accession no.
XP_810645). The corresponding CL Brener TcNTR residues are numbered 110–160 because of an insertion or deletion in the amino terminal domain.
Mutations in the corresponding region of E. coli nfsB that confer nitrofurantoin resistance are indicated by asterisks [31].
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in virulence. When Vero cells were used (Figure 4D), the
number infected by resistant clones was signiﬁcantly less than
the level observed with the parental sensitive parasites
(Figure 4E), and the average number of amastigotes per infect-
ed cell was reduced (Figure 4F). When L6 cells were infected
with drug-resistant metacyclics, although released trypomasti-
gotes could be observed, their numbers were too few for a
quantiﬁable infection assay to be performed. This compares to
an infection rate of approximately 25% in the case of the 61S
TcNTR heterozygotes and homozygotes (Figure 4B). These ex-
periments therefore suggest that functional loss of both TcNTR
genes, by the mechanisms identiﬁed here, is associated with a
reduction in virulence that would reduce the capacity of highly
drug-resistant parasites to spread within the population.
TcNTR Diversity and Benznidazole Sensitivity in the Field
To explore possible relationships between natural susceptibility
to benznidazole and TcNTR, we sequenced the gene from 28
Colombian strains of different biological and geographical
origins and with a range of benznidazole sensitivities (IC50,
1.5–35 μM) (Table 1). TcNTR length varied between 939 and
951 nucleotides in these strains, mainly because of changes in
the copy number of a trinucleotide (ATC)5-9 located between
residues 210 and 238. This region of the protein is not required
for enzyme activity [5]. Excluding this repeat, we identiﬁed 42
polymorphisms, 25 of which were nonsynonymous. These
amino acid differences were restricted to 7 strains, all but one
of human origin. None of the polymorphisms were located in
the region of TcNTR where we had identiﬁed mutations asso-
ciated with benznidazole resistance. Most were located in the
amino terminal extension (Supplementary Figure 2). The
major amino acid haplotype group encompassed 21 strains of
various biological and geographical origins. Importantly, these
had a wide range of benznidazole sensitivities (IC50, 4–35 μM)
(Table 1). This extensive natural variation is therefore indepen-
dent of TcNTR sequence and must be due to other factors.
This suggests that resistance arising from changes to TcNTR is
an acquired trait that requires selective pressure.
DISCUSSION
Despite being the frontline drug against T. cruzi infections
for >40 years, benznidazole has drawbacks [4, 32]. It can
have serious side effects, it requires long-term administration
(30–60 days), and its efﬁcacy against chronic stage disease is
inconsistent. Treatment failures are widely reported, although
Figure 3. Biochemical analysis of TcNTR from benznidazole (BNZ)-sensitive and -resistant Trypanosoma cruzi. A, Puriﬁcation of recombinant TcNTR.
Upper image, wild-type (WT; 61S) enzyme; lower, clone 4. Protein expression was induced by isopropyl-β-D-thiogalactopyranoside (Materials and
Methods), and a clariﬁed fraction (lane 1) was loaded onto a nickel–nitriloacetic acid column and the ﬂow-through collected (lane 2). The column was
washed with 50 mM and then 100 mM imidazole (lanes 3 and 4) and the recombinant protein eluted with 500 mM imidazole, 1% triton X-100 (lane 5).
The 32-kDa TcNTR band is highlighted by an arrow. Recombinant protein from each of the resistant clones was puriﬁed in a similar manner. B, TcNTR
activity was monitored (on the basis of absorbance [Abs] at a wavelength of 340 nm) by following oxidation of nicotinamide adenine dinucleotide,
reduced (NADH; 100 μM), in the presence of WT or mutant (P125L, clone 4) enzyme (0.2 μg) and BNZ (100 μM). C, Activity (v) of the WT enzyme (nmol
NADH per min per mg) was established by this assay with a ﬁxed concentration of NADH (100 μM) in the presence of different levels of BNZ
(10–100 μM). D, Fluorescence (excitation λ = 450 nm; emission λ = 535 nm) of the TcNTR cofactor (WT and P125L) and ﬂavin mononucleotide (FMN)
and ﬂavin adenine dinucleotide (FAD) controls (in arbitrary units) under acidic and neutral conditions (Materials and Methods). E, Activity of WT and
mutant TcNTRs.
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the extent to which this is an acquired trait or reﬂects diversity
in the level of susceptibility within natural parasite populations
is unknown [33]. As shown here and elsewhere [5, 34, 35], lab-
oratory selection of drug-resistant T. cruzi is readily achievable,
but in the case of benznidazole and nifurtimox, it is only re-
cently that a mechanism has been identiﬁed [5]. Activation of
these prodrugs by the trypanosome type I NTR, an enzyme
absent from mammals, is central to their mode of action and
explains why they are more toxic to the parasite than to the
host. The 61R benznidazole-resistant T. cruzi clones that we
investigated were characterized by loss of a 0.85-Mb chromo-
some band containing TcNTR. Genome plasticity is a common
phenomenon in trypanosomes [24]. Conﬁrmation that reduced
TcNTR expression caused this resistance was provided by re-
version of the phenotype following reintroduction of the gene.
Unexpectedly, we also found that in each of the 61R clones ex-
amined, the TcNTR gene on the 1.1-Mb chromosome homo-
logue had acquired missense mutation(s) that rendered the
expressed product enzymatically inactive (Figures 2 and 3).
The most parsimonious explanation for our data is that
drug pressure led initially to selection of benznidazole resis-
tance because of loss of the TcNTR-containing 0.85-Mb chro-
mosome. Continued treatment then resulted in selection, from
within this population, of distinct lineages in which mutation(s)
had inactivated the remaining TcNTR gene. The acquisition of
2 distinct missense mutations in TcNTR of clone 6 (nucleo-
tides 374 and 460) implies consecutive events. This 2-step
process is reminiscent of what happens in E. coli, where in-
creased nitrofuran resistance resulted from consecutive muta-
tions in the type I NTR genes nfsA and nfsB [31]. The mutant
TcNTR proteins were found to be deﬁcient in ﬂavin mononu-
cleotide binding. In the NTR group of enzymes, the location
of ﬂavin binding is highly conserved within the overall struc-
ture [30]. All of the mutations in TcNTR were restricted to a
region (residues 125–159; Figure 2) that, in the E. coli enzyme,
contains residues that interact with the isoalloxazine O2,
N3, O4 face of ﬂavin mononucleotide [30]. The mutation of
residue 125 resulted in conversion of an evolutionarily con-
served proline to a leucine (clones 1, 2, 4, 5, and 6). At position
154 in clone 6, proline was converted to alanine. Both changes
would be expected to perturb structure. In clone 3, the muta-
tion associated with disruption of ﬂavin mononucleotide
binding involved conversion of phenylalanine 159 to leucine.
Phenylalanine is present at the corresponding position in
E. coli and T. cruzi NTRs (Figure 2), suggesting a functionally
conserved role.
Figure 4. Loss of 1 copy of TcNTR does not reduce infectivity. Targeted disruption of TcNTR in 61S epimastigotes was achieved using a construct
that confers blasticidin resistance (Supplementary Figure 1). A, TcNTR heterozygotes are benznidazole resistant. 61S TcNTR homozygotes (+/+) and
heterozygotes (+/−) were tested to establish their median inhibitory concentration (IC50). Data are the mean (±SD) of 3 experiments. B, Heterozygotes
are not deﬁcient in infectivity. Cell-derived trypomastigotes were added to an L6 cell monolayer at a ratio of 1:5 cells to parasites. Infected cells were
counted after 72 hours, (experiment performed in triplicate, with data presented mean ± SD). C, Heterozygotes are not deﬁcient in their ability to
replicate in mammalian cells. Infections were performed and monitored as described above. D, Infection of Vero cells with 61S sensitive and 61R
resistant parasites, stained with Giemsa: (1) 61S; (2) 61R clone 3; (3) 61R clone 4; (4) 61R clone 6. Arrows indicate intracellular amastigotes 48 hours
after infection. E, Benznidazole-resistant clones are deﬁcient in their ability to infect Vero cells. Values shown are from 5 experiments (P < .05). (F )
Benznidazole-resistant clones are less able to replicate in Vero cells. Values shown are from 5 experiments (P < .05).
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The ability of distinct TcNTR-deﬁcient T. cruzi clones to
arise independently in a single population is strong evidence
that the drug-activating properties of this enzyme are central
to the trypanocidal mechanism. The TcNTR single knockouts
were 4-fold less susceptible to benznidazole (Figure 4), a level
of resistance that is signiﬁcant in the context of this drug, for
which the therapeutic window is limited [3]. The virulence
properties in vitro were also indistinguishable from TcNTR
homozygotes. This potential for benznidazole resistance by a
straightforward mechanism, coupled with the absence of
haploid insufﬁciency, may explain some of the observed treat-
ment failures. The inability of the 61S strain to produce a
patent infection in mice has restricted us from investigating
this further. Complete loss of TcNTR activity in the 61R
resistant clones did however have a detrimental effect on in-
fectivity in vitro (Figure 4). This implies that in vivo there will
be a limit to the extent of benznidazole resistance achievable
by mechanisms involving TcNTR (approximately 4-fold),
since parasites need to retain a residual level of enzyme activi-
ty. When we investigated possible relationships between sus-
ceptibility to benznidazole and TcNTR sequence in a diverse
group of parasites (Table 1), we found no correlation. These
data suggest that natural variation in sensitivity does not
involve mutations in TcNTR and that resistance by this
mechanism may be a trait that arises only after selective
pressure. Currently, there is no information on the extent
to which treatment failures reﬂect natural or acquired
resistance.
An observation, which has wider implications for treatment
of Chagas disease, is the ease with which drug resistance can
arise. In a single experiment, we identiﬁed 2 distinct mecha-
nisms, chromosome loss and point mutation, which acted to
reduce TcNTR activity. In the latter case, 3 distinct, indepen-
dently acquired mutations were identiﬁed. T. cruzi is extremely
diverse, with a genome characterized by extensive and highly
variable surface antigen gene families [36]. This antigenic di-
versity may have arisen in response to selective immune pres-
sure during evolution, which acted to limit the proofreading
ability of DNA polymerase and/or DNA repair mechanisms.
As a consequence, the parasite may have acquired an ability to
readily develop drug resistance by mutational mechanisms
such as those described here. This is an important consider-
ation that should inform drug development strategies for
Chagas disease.
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